title: Inhibition of focal adhesion kinase suppresses the adverse phenotype of endocrine-resistant breast cancer cells and improves endocrine response in endocrine-sensitive cells.
abstract: Acquired resistance to endocrine therapy in breast cancer is a major clinical problem. Previous reports have demonstrated that cell models of acquired endocrine resistance have altered cell-matrix adhesion and a highly migratory phenotype, features which may impact on tumour spread in vivo. Focal adhesion kinase (FAK) is an intracellular kinase that regulates signalling pathways central to cell adhesion, migration and survival and its expression is frequently deregulated in breast cancer. In this study, we have used the novel FAK inhibitor PF573228 to address the role of FAK in the development of endocrine resistance. Whilst total-FAK expression was similar between endocrine-sensitive and endocrine-resistant MCF7 cells, FAK phosphorylation status (Y397 or Y861) was altered in resistance. PF573228 promoted a dose-dependent inhibition of FAK phosphorylation at Y397 but did not affect other FAK activation sites (pY407, pY576 and pY861). Endocrine-resistant cells were more sensitive to these inhibitory effects versus MCF7 (mean IC(50) for FAK pY397 inhibition: 0.43 μM, 0.05 μM and 0.13 μM for MCF7, TamR and FasR cells, respectively). Inhibition of FAK pY397 was associated with a reduction in TamR and FasR adhesion to, and migration over, matrix components. PF573228 as a single agent (0-1 μM) did not affect the growth of MCF7 cells or their endocrine-resistant counterparts. However, treatment of endocrine-sensitive cells with PF573228 and tamoxifen combined resulted in greater suppression of proliferation versus single agent treatment. Together these data suggest the importance of FAK in the process of endocrine resistance, particularly in the development of an aggressive, migratory cell phenotype and demonstrate the potential to improve endocrine response through combination treatment.
authors.affiliation: Welsh School of Pharmacy, Cardiff University, Redwood Building, Kind Edward VII Avenue, Cathays Park, Cardiff, CF10 3NB, UK. HiscoxSE1@cf.ac.uk
authors.forename: Stephen
authors.initials: S
authors.lastname: Hiscox
authors.forename: Peter
authors.initials: P
authors.lastname: Barnfather
authors.forename: Edd
authors.initials: E
authors.lastname: Hayes
authors.forename: Pamela
authors.initials: P
authors.lastname: Bramble
authors.forename: James
authors.initials: J
authors.lastname: Christensen
authors.forename: Robert I
authors.initials: RI
authors.lastname: Nicholson
authors.forename: Peter
authors.initials: P
authors.lastname: Barrett-Lee
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D001943:Breast Neoplasms / Q000201:enzymology* / Q000628:therapy*; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D002465:Cell Movement; D004305:Dose-Response Relationship, Drug; D004703:Endocrine System; D004791:Enzyme Inhibitors / Q000494:pharmacology; D004958:Estradiol / Q000031:analogs & derivatives / Q000494:pharmacology; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*; D000077267:Fulvestrant; D006801:Humans; D020128:Inhibitory Concentration 50; D010641:Phenotype; D015363:Quinolones / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology
chemical_list: C521108:6-(4-(3-(methylsulfonyl)benzylamino)-5-(trifluoromethyl)pyrimidin-2-ylamino)-3,4-dihydroquinolin-2(1H)-one; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D015363:Quinolones; D013450:Sulfones; D013629:Tamoxifen; D000077267:Fulvestrant; D004958:Estradiol; D051416:Focal Adhesion Protein-Tyrosine Kinases